News Releases

February 27, 2014

RepliCel to Present RCH-01 Phase 1 Clinical Data at the 13th Congress of the Japanese Society for Regenerative Medicine
VANCOUVER, BC – February 27, 2014 – RepliCel Life Sciences Inc. (OTCQB: REPCF) (TSXV: RP) announced that its Director of Research and Development, Dr.... Read full article

February 26, 2014

RepliCel Retains Ubika Communication for Online Capital Market Exposure
VANCOUVER, BC – February 26, 2014 – RepliCel Life Sciences Inc. (TSXV: RP) (OTCQB: REPCF), today announced that it has retained Ubika Communication, a... Read full article

January 13, 2014

RepliCel Receives Japanese Patent Covering its Hair Regeneration Technology
VANCOUVER, BC – January 13, 2014 – RepliCel Life Sciences Inc. (OTCQB: REPCF) (TSXV: RP) today announced that it has been granted a patent... Read full article

January 9, 2014

RepliCel Life Sciences to Present at Biotech Showcase™ 2014
Vancouver, Canada – January 9, 2014 – RepliCel Life Sciences Inc. (OTCQB: REPCF) (CSE: RP), a clinical stage biopharmaceutical company focused on developing therapies... Read full article

January 9, 2014

RepliCel to Commence Trading on the TSX Venture Exchange
VANCOUVER, BC – January 9, 2014 – RepliCel Life Sciences Inc. (OTCQB: REPCF) (CSE: RP) is pleased to announce that its common shares are... Read full article

January 2, 2014

RepliCel Announces Conditional Approval from TSX Venture Exchange
VANCOUVER, BC – January 2, 2014 –RepliCel Life Sciences Inc. (the “Company” or “RepliCel”) (OTCQB: REPCF) (CNSX: RP) is pleased to announce that it has received... Read full article

December 19, 2013

RepliCel Reports Progress on Shiseido Technology Transfer for RCH-01 Treatment for Pattern Baldness
VANCOUVER, BC – December 19, 2013 – RepliCel Life Sciences Inc. (OTCQB: REPCF) (CNSX: RP) today reported on the progress of its technology transfer agreement... Read full article

November 20, 2013

RepliCel Reports Third Quarter 2013 Financial Results and Provides Corporate Update
VANCOUVER, BC – November 20, 2013 – RepliCel Life Sciences Inc. (OTCQB: REPCF) (CNSX: RP), a clinical stage regenerative medicine company focused on the... Read full article

October 30, 2013

RepliCel Forms Clinical Advisory Board to Support the Development of RCT-01 for the Treatment of Chronic Tendinosis
VANCOUVER, BC – October 30, 2013 – RepliCel Life Sciences Inc. (OTCBB: REPCF) (CNSX: RP),  a clinical stage biopharmaceutical company focused on the development of... Read full article

September 6, 2013

RepliCel Announces Stock Option Grant
VANCOUVER, BC – September 6, 2013 – RepliCel Life Sciences Inc. (OTCBB: REPCF) (CNSX: RP), a clinical stage biopharmaceutical company focused on the development... Read full article